Share, Send, or Save

Pipeline

Alexion is advancing a rare disease pipeline that builds on our fundamental strength in complement biology and focuses on our core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

Full Pipeline

Market
Advanced Clinical Development
Early Clinical
Development
Preclinical
Filter by:
 
 
Generate PDF
 

Soliris® (eculizumab) for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase: Market

 
 

Soliris® (eculizumab) for Atypical Hemolytic Uremic Syndrome (aHUS)
Phase: Market

 
 

Soliris® (eculizumab) for AchR+ Generalized Myasthenia Gravis (gMG)
Phase: Market

 
 

Strensiq® (asfotase alfa) for Hypophosphatasia (HPP)
Phase: Market

 
 

Kanuma® (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D)
Phase: Market

 
 

Soliris® (eculizumab) for Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase: Advanced Clinical Development

 
 

ALXN1210 IV for PNH
Phase: Advanced Clinical Development

 
 

ALXN1210 IV for aHUS
Phase: Advanced Clinical Development

 
 

ALXN1210 Subcutaneous QW
Phase: Early Clinical Development

 
 

ALXN1210 for Generalized Myasthenia Gravis (gMG)
Phase: Preclinical

 
 

ALXN1210 for IgA Nephropathy (IgAN)
Phase: Preclinical

 
 

ALXN1210 Next-Generation Subcutaneous Q2W or Q4W
Phase: Preclinical

 
 

Multiple Complement
Phase: Preclinical